AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 302 min read$ANIP

CAREY STEPHEN P. sold $232K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 2,850 shares of ANI PHARMACEUTICALS INC (ANIP) at $81.36 ($0.23M total) on 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Jul 30, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIP
Neutral
high confidence
Mentioned
$ANIP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

For traders, the main use is monitoring insider activity and potential sentiment, but the planned nature of the sale reduces informational content.

02

Market read

A routine planned insider sale is disclosed; absent other catalysts, it is unlikely to drive a durable repricing.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, changes in guidance, or new company-specific catalysts.

Relevance 3/10Novelty 3/10Timing: filed July 30, transaction dated July 29

Background

The article is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals, showing an open-market sale by the CFO under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$ANIPNeutralHigh confidence
Context

ANI Pharmaceuticals disclosed an SVP and CFO open-market sale of 2,850 shares at $81.36 on a 10b5-1 plan, filed July 30.

Expected impact

Likely minimal immediate price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 details a planned open-market transaction by an executive, without any accompanying guidance, operational update, or regulatory action in the text.

Market effects

Sector

No sector-wide implications are stated; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales under a 10b5-1 plan can reflect liquidity planning rather than bearish expectations, so the market may overreact.

Key entities

  • issuer
    ANI Pharmaceuticals Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    CAREY STEPHEN P.

    SVP and CFO who sold 2,850 shares at $81.36 on July 29 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIP insider trading history →

Related articles

OCT 12
$ANIPHighAI 8/10

ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study

ANI Pharmaceuticals (ANIP) reported positive results from its Phase 4 SYNCHRONICITY trial for the Fluocinolone Acetonide Intravitreal Implant in treating chronic non-infectious uveitis affecting the posterior segment of the eye. The trial met primary endpoints at six months and maintained improvements through 24 months. The implant is approved in the U.S. for chronic NIU-PS and diabetic macular edema. ANIP's stock closed at $73.89, up 2.65%.

rttnews.com2 min
OCT 12
$ANIPMedAI 8/10

ANI reports positive results from uveitis implant trial

ANI Pharmaceuticals (NASDAQ:ANIP) reported positive Phase 4 trial results for its fluocinolone acetonide implant in treating chronic non-infectious uveitis. The trial met primary endpoints, showing sustained improvements in visual acuity and central subfield thickness over 24 months. Adverse events included ocular hypertension and cataract. The implant was previously FDA-approved for diabetic macular edema and uveitis treatment.

investing.com2 min
OCT 12
$ANIPMedAI 8/10

After one implant, 79.6% of treated eyes had no inflammation return for two years

ANI Pharmaceuticals reported 6-month and 24-month data from its SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis. The trial met co-primary endpoints with statistical significance, showing improvements in visual acuity and central subfield thickness. At 24 months, 79.6% of treated eyes had no inflammation recurrence. Adverse events were consistent with prior trials.

stocktitan.net2 min
SEP 30
$ANIPMedAI 8/10

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals (ANIP) will present data from its Phase 4 SYNCHRONICITY trial and post-hoc analyses from the NEW DAY trial at the American Academy of Ophthalmology 2026 Meeting. The trials involve Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis and diabetic macular edema. The company also plans an encore presentation at the Hawaiian Eye & Retina 2027 Meeting.

globenewswire.com1 min